arrow
T

Tempei Miyaji

University of Tokyo
H指数:17
被引数:1,770

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 − advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)

通过移动应用程序和可穿戴设备收集的HR+/HER2−晚期乳腺癌患者接受帕博西利比联合内分泌治疗或单纯内分泌治疗后的健康相关生活质量与身体活动:6个月纵向研究(JBCRG-26)

2025-07-180
OA
Health-related QOL and physical activity collected via wearable device in patients with HR+/HER2-advanced breast cancer in Japan treated with palbociclib plus endocrine therapy (ET) or ET alone: 6-month longitudinal study (JBCRG-26)
2024-05-020
PRE
Optimizing smartphone psychotherapy for depressive symptoms in patients with cancer: Multiphase optimization strategy using a decentralized multicenter randomized clinical trial (J-SUPPORT 2001 Study)
2024-03-114
OA
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)
2023-11-168
OA
Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research The PRO Ethics Guidelines
2022-05-1728
OA
Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation
2021-11-0117
OAAI
Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial
2021-09-013
OAAI
Additive Duloxetine for Cancer-Related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08)

添加度洛西汀治疗对阿片类药物-普瑞巴林治疗无反应或不耐受的癌症相关神经性疼痛: 一项随机对照试验 (JORTC-PAL08)

2019-10-0128
OAAI
Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial

局部类固醇与安慰剂预防接受放化疗的头颈癌患者放射性皮炎的比较: j-support 1602 (TOPICS研究) 的研究方案,一项随机双盲3期试验

2018-09-0615
OAAI